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Current asthma therapies fail to target airway remodeling which correlates with asthma severity 
driving disease progression that ultimately leads to loss of lung function. Macroautophagy 
(here after autophagy) is a fundamental cell recycling mechanism in all eukaryotic cells; 
emerging evidence suggests that it is dysregulated in asthma. We investigated the 
interrelationship between autophagy and airway remodeling and assessed preclinical efficacy 
of a known autophagy inhibitor in murine models of asthma. Human asthmatic and non-
asthmatic lung tissues were histologically evaluated and were immuno-stained for key 
autophagy markers. The percent area of positive staining was quantified in the epithelium and 
airway smooth muscle (ASM) bundles using ImageJ software. Furthermore, autophagy 
inhibitor chloroquine (CQ) was tested (i.n.) in prophylactic (3-weeks) and treatment (5-weeks) 
models of allergic asthma in mice. Human asthmatic tissues showed greater tissue 
inflammation and demonstrated hallmark features of airway remodeling displaying thickened 
epithelium (p<0.001) and reticular basement membrane (p<0.0001), greater lamina propria 
depth (p<0.005), and increase in ASM bundles (p<0.001) with higher expression of Beclin1 
(p<0.01) and ATG5 (p<0.05) along with reduced p62 (p<0.05) compared to non-asthmatic 
controls. Beclin1 expression was significantly higher in asthmatic epithelium and ciliated cells 
(p<0.05) suggesting potential role of ciliophagy in asthma. Murine asthma models 
demonstrated effective preclinical efficacy (reduced key features of allergic asthma: airway 
inflammation, AHR and airway remodeling) of autophagy inhibitor CQ. Our data demonstrates 
cell-context dependent, and selective activation of autophagy in structural cells in asthma. 
Further, this pathway can be effectively targeted to ameliorate airway remodeling in asthma. 
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Asthma is a complex and heterogeneous condition characterized by spontaneous 
bronchoconstriction accompanied by widespread but variable airflow obstruction. Various 
genetic and environmental factors interplay in an array of disorders amalgamating in the 
classical triadic asthma phenotype of airway inflammation, remodeling and airway 
hyperresponsiveness (AHR) (1). Therapeutically, only inflammation and airway 
hyperresponsiveness can be sufficiently attenuated. The third pathophysiological link in the 
triadic asthma phenotype is airway remodeling, which needs attention. Airway smooth muscle 
(ASM) mass, mucous gland hypertrophy, neo-angiogenesis in the submucosa, sub epithelial 
fibrosis, increased mucus secretion (by goblet cells), epithelial fragility and epithelial-
mesenchymal transition (EMT) are defining features of airway remodeling in asthma (2). ASM 
hyperplasia and hypertrophy in the central airways are both indicators and traits of asthma 
severity (3). Current therapeutics do not effectively target progressive airway fibrosis and 
remodelling. Elevated basal concentrations of transforming growth factor β (TGFβ) in 
asthmatics has been associated with sustained characteristic airway remodeling (4, 5). 
Alongside having a multitude of effects in homeostasis and pathophysiology of disease, TGFβ 
is thought to drive airway remodeling through the activation of myofibroblasts and smooth 
muscle cells, subsequently inducing the release of fibrogenic extracellular matrix (ECM) 
proteins (6). Emerging data suggest that autophagy promotes and influences this classical 
TGFβ driven airway remodeling (7). Autophagy modulation may therefore be a novel effective 
therapy for unmanageable asthma.  
Autophagy is a fundamental cellular and physiological process that occurs in all 
eukaryotic cells (8). The cellular process can be informally referred to as the inner recycling 
mechanism or a process of “self-eating”. Targeted components are sequestered in double-
membrane autophagosomes and ultimately degraded upon fusion with a lysosome with the 
cytoplasmic components recycled (9). Autophagy is a crucial regulator in the pathogenesis of 
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human disease as it has the potential to influence innate immune responses and promote 
programmed cell death along with the ability to regularly remove aging proteins, large 
molecular complexes, and obsolete or damaged organelles (9). The Beclin-1/class III 
Phosphoinositide 3-kinase (PI3K) complex is integral in autophagosomal membrane 
nucleation (10). Autophagy-related gene 5 (ATG5) is covalently conjugated with ATG12 and 
interacts with ATG16 to form the ATG12-ATG5-ATG16 complex. This complex is associated 
with autophagosome elongation and is essential for autophagosome formation (9). During 
autophagy, a truncated cytosolic form of Microtubule-associated proteins 1A/1B light chain 
3A (LC3), LC3-I is conjugated to Phosphatidylethanolamine (PE) to form the membrane bound 
LC3-II (9). Punctate LC3-II is visible with immunostaining and indicates complete formation 
of autophagosomes (11). Sequestosome-1 (SQSTM1/p62) is a ubiquitin-binding protein that 
targets and binds to other proteins for selective autophagy which are ultimately degraded in the 
lysosome (12). p62 accumulates when autophagy is inhibited and inversely, levels of p62 
decrease when autophagy is induced (13, 14). Whilst autophagy routinely plays a protective 
role, its functions such as cell survival can be deleterious (15).  
Autophagy is involved in the pathogenesis of various diseases and links between 
autophagy and asthma are emerging (16-18). A positive correlation of ATG5 and collagen 
alpha-1 (V) gene expression in the airways of patients with refractory asthma supports this link 
between dysregulated autophagy and fibrosis in the airways (19). ECM-regulated autophagy is 
proposed to maintain tissue homeostasis and thus dysfunctional autophagy in the presence of 
increased TGFβ may propel the progression of airway remodeling (20). In this study we have 
found the evidence of activation of autophagy pathway in the small and large airways from 
asthmatic patients. The localization of autophagy proteins in the asthmatic airways is restricted 
to structural cells in the airway wall and is associated with features of airway remodeling in a 
TGFβ-dependent manner. We found that TGFβ concomitantly induced autophagy and 
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profibrotic signaling in ASM cells, this induction was prevented by CQ in vitro.  Further, using 
mouse models of allergic asthma, we demonstrated that targeting autophagy pathway is an 
efficient way of providing therapeutic benefit in asthma.  
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Materials and methods 
Acquisition of human lung tissue 
Human lung tissue was obtained from surgical resection, explanted lungs and post 
mortem organ donors with ethical approval from Royal Prince Alfred Hospital, Concord 
Repatriation General Hospital and St Vincent’s Hospital (# HREC14-0045, Sydney).  
Human subject classification 
See the data supplement for full subject classification.  
Human Lung Tissue Processing and Section Preparation 
Dissected lung tissues were fixed, processed and embedded in paraffin for analyses 
(21). Following microtome sectioning, Haematoxylin and Eosin (H&E) staining and masson’s 
trichrome staining were used to assess structural integrity, inflammation and features of airway 
remodeling. See the data supplement for full methods. 
Morphometric analysis of inflammation and airway remodeling features 
Lamina propria depth was measured perpendicularly from multiple points at the base 
of the reticular basement membrane (RBM) to the outer edge of ASM bundles, and the 
proportion of ASM in the airway wall (ASM/LP, %) was calculated by measuring the total area 
of ASM mass per airway and dividing by the total area of lamina propria. Overall tissue 
inflammation in the lung was assessed and immune cells were counted manually in the lung 
tissue as described in data supplement. 
Immunohistochemistry and immunofluorescent staining 
Immunostaining for Beclin-1, ATG5, LC3B, p62 and sm-a-actin was performed as 
previously described (22-24). See the data supplement for full methods. 
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Image analysis 
Computer-assisted image analysis was performed with a NanoZoomer-SQ Digital slide 
scanner (Hamamatsu, Hamamatsu City, Japan), Olympus BX51 upright epifluorescence 
microscope fitted with a DP70 CCD camera (Olympus, Shinjuku, Japan) and ImageJ software.  
Cell culture  
Human ASM cells were obtained from human lung by a method as described 
previously, see the data supplement for full methods. 
 
Mouse models of allergic asthma 
Experiments were conducted according to the institutional guidelines and the code for 
the care and use of animals. Animal Care Committee of Thomas Jefferson University and UTS 
approved the protocol. All surgeries were performed under tribromoethanol anesthesia, and all 
efforts were made to minimize suffering. BALB/c mice (female) were subjected to a sub-
chronic (prophylactic) model of allergic asthma as described and shown in Fig 8A. 30 minutes 
prior to HDM challenges, selected mice were administered either chloroquine (CQ) intra 
nasally (50mg/kg) or saline as a vehicle. In a separate study BALB/c mice (female) were 
subjected to a treatment model (chronic allergic asthma model) of asthma as described and 
shown in Fig 9A. At week four and commencing for two weeks, 30 minutes prior to HDM 
challenges, selected mice were administered either chloroquine (CQ) intra nasally (50mg/kg) 
or vehicle (saline). In both studies, 24h after the last HDM challenge, lung function 
measurements were performed (flexiVent, Scireq, Montreal, Canada), bronchoalveolar lavage 
(BAL) fluid was collected, and lungs were formalin-fixed or flash frozen for histopathology 
and biochemical analysis. See the data supplement for full methods. 
 
Mouse BAL immune cell staining, lung H&E, PAS and Masson’s trichrome Staining 
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BAL sample cytospins were prepared and stained with Hema-3 staining kit (Fisher 
Scientific, Hampton, USA). The fixed lung tissues embedded in paraffin were cut and stained 
with H&E, PAS and Masson’s trichrome staining using a protocol described previously (25-
27). See the data supplement for full methods. 
 
Measurement of TGFβ1 
 
The content of TGFβ1 in BAL fluid was measured by Multiplexing LASER Bead 
Technology (Eve Technologies, Calgary, Canada) using a custom TGF-beta 3-Plex Cytokine 
Array. 
Western blotting  
 
 Protein levels of Collagen 1A, pSMAD2/3, SMAD2/3, Beclin1 and LC3B in ASM cell 
lysates or murine lung tissues were measured by immunoblotting. All immunoblotting was 
carried out using protocols described previously (26, 28). See the data supplement for full 
methods. 
 Soluble Collagen Assay 
 
 Total soluble collagen content in the lung lysates was assessed using Sircol collagen 
assay (Biocolor, Carrickfergus, UK) (29). See the data supplement for full methods.  
Statistical analysis 
 
Data was analyzed using unpaired t-tests or one-way or two-way ANOVA as 
appropriate and is presented as mean ± SD or ± SEM. All data was analyzed with PRISM 




Histological evidence of airway remodeling and inflammation 
As the link between autophagy and airway remodeling has been established, we first 
chose to histologically measure remodeling features of our selected asthmatic and non-
asthmatic patients. Asthmatic airways in comparison with non-asthmatic airways displayed 
greater features of airway remodeling. Gross remodeling changes between non-asthmatic and 
asthmatic large airways were observed utilizing trichrome staining (Fig. 1A-F). The average 
epithelium thickness was significantly greater in asthmatics than in non-asthmatics (A: 
50.46μm ± 9.52 vs. NA: 27.46μm ± 9.16, p<0.001) and with aniline blue dye staining of the 
fibrous RBM we observed an overall increase in thickness of the RBM in asthmatics (A: 
9.94μm ± 1.63 vs. NA: 5.32μm ± 0.93, p<0.0001) (Fig. 1G-H). The average lamina propria 
(LP) depth for asthmatics was significantly thicker than non-asthmatics (A: 235.71μm ± 81.97 
vs. NA: 105.31μm ± 48.81, p<0.05) and staining of acidophilic tissue components (cytoplasm 
and muscle) with biebrich scarlet-acid fuchsin allowed us to measure and observe an increase 
in the percentage of ASM mass in asthmatic LP (A: 20.63% ± 7.01 vs. NA: 8.99% ± 3.16, 
p<0.001). (Fig. 1I-J). These measurements classify the selected asthmatic patients as having 
undergone associated airway remodeling and justify their inclusion into the 
immunohistological component of this study. We further assessed tissue inflammation in the 
lungs by scoring overall airway wall inflammation (Fig. 1K) which showed greater influx of 
immune cells in the asthmatic airways. Nature of immune cell influx was determined by 
counting eosinophils (Fig. 1L), neutrophils (Fig. 1M) and macrophages (Fig. 1N). As shown 




Expression profile of autophagy marker proteins in the large airways of asthmatics  
We have selected four key markers of autophagy to examine their expression in the 
epithelial and ASM components of small and large airway walls in conjunction with normal 
non-asthmatic histology and remodeled asthmatic histopathology. There were no significant 
differences in the large airway epithelium (Fig. 2); while in the large airway ASM bundles we 
observed a marked increase in the expression (% area ± SD) of Beclin1 (A: 16.78% ± 9.38 vs. 
NA: 5.16 % ± 3.07, p<0.01) and ATG5 (A: 4.23% ± 2.09 vs. NA: 1.94% ± 1.94, p<0.05), and 
a decrease in p62 expression (A: 1.65% ± 1.06 vs. NA: 3.41% ± 2.31, p<0.05) in asthmatics 
compared with non-asthmatics (Fig. 3).  
 
Expression profile of autophagy markers in the small airways of asthmatics  
In the small airway epithelium, we observed solely a marked increase in the expression 
(% area ± SD) of Beclin1 (A: 19.44% ± 7.31 vs. NA: 11.44% ± 4.63, p<0.05) (Fig. 4), with no 
significant differences in small airway ASM bundles (Fig. 5).  
 
 
Expression of Beclin-1 in cilia lining the large airways of asthmatics 
In accordance with our classification, five out of six asthmatic patients displayed strong 
expression of Beclin-1 in the cilia lining the large airway epithelium whilst only one out of ten 
non-asthmatic patients displayed any expression of Beclin-1 in the cilia of the large airway 
epithelium. Overall, we have demonstrated that strong expression of Beclin1 in cilia lining 
large airway epithelial cells occurs mostly in asthmatic patients with associated airway 
remodeling evident compared to non-asthmatics (Fig. 6 A-C). Other markers (ATG5, LC3B, 




Concomitant induction of pro-fibrotic signaling and autophagy markers in human airway 
smooth muscle cells 
 Greater tissue inflammation in the asthmatic lungs is in congruence with the published 
literature and supports the tenet that inflammation can partly drive airway remodeling in 
asthma. Therefore, we tested this hypothesis whether TGF1(a pleiotropic cytokine, elevated 
in asthma) would concomitantly induce pro-fibrotic signaling and autophagy in vitro. As shown 
in Fig 7, we found that TGF1 in a time-dependent manner increased collagen-1 expression 
and SMAD2/3 phosphorylation (pro-fibrotic signaling) and induced autophagy in ASM cells 
as seen with increased expression of Beclin-1 and LC3BII (Fig. 7A). This demonstrates an 
association between the effects of TGF1, the accumulation of collagen and increased pro-
fibrotic signaling in an autophagy-dependent manner. 
 
Effect of autophagy inhibitor on the concomitant induction of pro-fibrotic signaling and 
autophagy markers in human airway smooth muscle cells 
 Furthermore, we tested in vitro whether the treatment with autophagy inhibitor, CQ, 
would alleviate pro-fibrotic signaling and the induction of autophagy by TGF1 stimulation. 
As shown in Fig 7, we found that treatment with CQ (50µM) in conjunction with TGF1 
stimulation reduced the expression of collagen 1A, Beclin-1 and LCB3-II, and the 
phosphorylation of SMAD2/3 in a time-dependent manner (Fig 7). This shows that CQ reduced 
TGF1 -induced airway remodeling markers in an autophagy dependent (inhibition) manner. 
 
Effect of autophagy inhibitor in a prophylactic model of allergic asthma 
To further investigate the interplay between autophagy and asthma we studied the 
effects of autophagy inhibition in an allergen (HDM)-induced asthma in mice (prophylactic 
model) as shown in Fig 8A. CQ is a known inhibitor of autophagy, increasing the pH of 
lysosomes and inhibiting fusion and formation of the autophagolysosome. Increased 
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inflammatory cell infiltration in both the airway wall and in the BAL, along with increased 
production of mucus are observed in the HDM-challenged mice in comparison with control 
mice (Fig. 8). Autophagy inhibitor effectively blocked influx of immune cells into the airways 
(Fig. 8 B, C, D, K) and significantly reduced eosinophils and neutrophils in the BAL fluid with 
no effect on macrophages (Fig. 8 L, M, N). Tissue inflammation was also reduced in the mouse 
lungs treated with CQ (Fig. 8 E, F, G: H&E staining) and there was a reduction in the mucus 
production in HDM-challenged mice treated with an autophagy inhibitor CQ (Fig. 8 H, I, J: 
PAS: airway mucus).  
To examine the connection of autophagy with airway remodelling we performed assays 
to measure levels of TGFβ1 in the BAL, soluble lung collagen and immunoblot analysis of 
Collagen 1, Beclin-1 and ATG-5 expression in the lung lysates. The HDM-challenged group 
showed significant increase in the concentration of TGFβ1 in the BAL compared with controls 
(p<0.001), while treatment with CQ significantly reduced TGFβ1 levels when compared with 
the HDM group (p<0.05) (Fig. 8O). Further we found significantly greater amount of soluble 
lung collagen in tissue lysates of HDM-challenged group when compared to the controls 
(p<0.001), while lysates from the CQ treated group showed a significant reduction in the 
amount of soluble collagen in comparison with the HDM group (p<0.05) (Fig. 8P). Lung 
function measurements using flexivent showed increased AHR in HDM-challenged mice to 
methacholine (MCh) when compared with control animals (increase in airway resistance (Rn) 
at 25, 50 and 100 mg/ml) while CQ treatment prevented development of AHR in mice 
(significant reduction in Rn at 25, 50 and 100 mg/ml) when compared to HDM-challenged 
group (Fig. 8Q). Immunoblotting in lung lysates revealed higher and concomitant expression 
of ECM protein Collagen 1A and autophagy markers Beclin-1 and ATG-5 in the HDM-
challenged mice when compared to controls, while CQ treatment prevented induction of 
 13 
autophagy (as shown by the reduction in Beclin-1 and ATG-5) and accumulation of collagen 
in the lung (Fig. 8R).  
 
Effect of autophagy inhibitor in a chronic model of allergic asthma 
We further employed an allergen (HDM)-induced mouse model of chronic asthma 
(treatment model) to investigate the role of autophagy in airway remodeling in asthma (Fig. 
9A). Mass inflammatory cell influx was observed in the airways of mice challenged with HDM 
and this was significantly attenuated in the CQ+HDM treated mice (Fig. 9B: H&E). Similar 
reduction was observed in the accumulation of fibrotic proteins in the CQ+HDM treated group 
when compared with HDM group (Fig. 9B: Mason trichrome). Increased production of mucus 
was observed in the HDM-challenged mice in comparison with saline-controls and was greatly 
reduced in CQ+HDM treated group (Fig. 9B: PAS). We further carried out immunofluorescent 
imaging for ASM marker: sm-𝛂-actin; chronic allergen challenge increased ASM bundles 
which were significantly reduced by CQ treatment (Fig. 9B: sm-𝛂-actin). 
Immunohistochemical staining was used to examine the expression of four key protein 
markers of autophagy in the airways of saline-control, HDM-challenged, and CQ+HDM 
treated mice. In the ASM bundles of the HDM-challenged mice we observed a marked increase 
in the expression (% area ± SD) of Beclin1 (HDM: 14.67% ± 3.02 vs. control: 6.98 % ± 3.08, 
p<0.0001) (Fig. 9D), ATG5 (HDM: 18.7% ± 3.99 vs. control: 11.27% ± 6.67, p<0.05) (Fig. 
9E) and LC3B (HDM: 20.47% ± 14.67 vs. control: 2.97% ± 1.59, p<0.05)(Fig. 9F) in the HDM-
challenged mice compared with control mice. Treatment with CQ significantly reduced the 
expression of Beclin1 (CQ+HDM: 7.5% ± 4.65 vs. HDM: 14.67% ± 3.02, p<0.0001)(Fig. 9D), 
ATG5 (CQ+HDM: 7.78% ± 7.18 vs. HDM: 18.7% ± 3.99, p<0.001)(Fig. 9E) and increased the 
expression of p62 (CQ+HDM: 7.27% ± 1.97 vs. HDM: 2.82% ± 2.09, p<0.0005) (Fig. 9G) in 
the CQ+HDM treated mice compared with HDM-challenged mice.  
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Discussion 
The upregulation of markers of autophagy has been linked with fibrosis and remodeling 
in various organs (7, 30). However, there has been limited histopathological evidence to show 
similar trends in the lungs of asthmatic patients. Whilst there are early reports on increased 
gene expression of ATG5 with additional measurement of ATG5 protein expression in the 
airways of refractory asthmatics (16, 19), our study provides comprehensive analysis of 
multiple autophagy markers and its association with airway remodeling in asthma. More 
importantly our data on Beclin-1 expression in both large and small airways and in the ciliated 
cells provides novel insight by which autophagy pathway may regulate and control airway 
remodeling in asthma. Further, this is also replicated in the murine models where we found 
induction of autophagy in experimental asthma models with a concomitant expression of pro-
fibrotic cytokines and collagen in the lung, which were attenuated in presence of an autophagy 
inhibitor. 
Firstly, we confirmed that the tissues we used displayed classical features of airway 
remodeling (5). There are variety of factors that contribute to the pathogenesis of asthma and 
subsequent development of airway remodeling in asthma. It is suggested that persistent insult 
leading to chronic inflammation with time leads to the development of structural changes in 
the lung that tracks clearly with significant reduction in the lung function and increase in 
asthma severity (31). Expression of Beclin-1 and ATG5 were found to be increased in the large 
airway ASM of asthmatics compared with healthy non-asthmatics, along with reduced 
expression of p62 in the large airway ASM of asthmatics compared with healthy non-
asthmatics. Therefore, in this cohort of patient population we found concomitant expression 
and association of autophagy with airway remodeling and inflammation. These findings are 
novel in asthma as there is no evidence to date suggesting expression of autophagy being 
closely associated with airway remodeling. This finding is reinforced by data from our chronic 
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HDM model of allergic asthma in mice in which we found increased expression of Beclin-1, 
ATG5 and LC3B in the ASM bundles of HDM-challenged mice when compared with the 
controls. This work clearly supports the published literature from kidney, liver and other organs 
where it has been shown that autophagy regulates tissue fibrosis (32, 33). On the other hand, it 
has been recently reported that autophagy is a necessary mechanism for changing the 
phenotype of lung epithelial cells to mesenchymal cells (34, 35) therefore current finding which 
shows incidence of autophagy in epithelium of asthmatic patient and HDM challenged mice 
might confirm the role of EMT in accumulation of mesenchymal cells in asthma pathogenesis.    
Airway remodeling features such as thickening of basement membrane is a key 
indicator for the development of asthma later in life; basement membrane thickening has been 
seen at an early age in children at 3-4 years of age (36). This led us to think about various 
signaling pathways such as autophagy that can be aberrant and can contribute to disease 
development later in life. While this needs to be investigated in samples from children, our data 
from adult asthmatics uncover the novel fundamental mechanism (autophagy) that may act as 
a key determinant of airway remodeling in asthma. Similarly, airway smooth muscle mass is 
increased in asthma and correlates with poor lung function and increased airway 
responsiveness to variety of contractile agonists, allergens, pollens etc. Our data from human 
lungs is clearly demonstrating a link between increased accumulation of ASM mass and 
increased expression of autophagy markers in the asthmatic lung, a feature totally absent in the 
non-asthmatic human lung. If these results are replicated in a larger cohort of asthma patients 
then we can direct our research efforts to selectively target mesenchymal cells using novel 
formulation and chemistry approaches which will lead to reduced mesenchymal cell mass, 
reduction in release of ECM proteins, and ultimately reduction in the ability of the airways to 
contract to variety of triggers. 
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An increase in the protein expression of Beclin-1 was also observed in the small airway 
epithelium compared with healthy non-asthmatics. With access to tissue for a greater number 
of patients, then accompanying significant differences in protein expression of Beclin1 and 
ATG5 in the large airway epithelium may be observed. Interestingly asthmatic epithelium 
displayed strong expression of Beclin-1 in cilia, while non-asthmatic epithelium did not display 
these levels of expression. The comparative expression of Beclin-1 in cilia of asthmatic and 
non-asthmatic epithelium has a significant binary pattern. In chronic obstructive pulmonary 
disease (COPD), autophagy-dependent pathways regulate cilia length upon exposure to 
cigarette smoke (37). The identification of an over-expression of Beclin-1 in ciliated cells of 
asthmatics highlight a role for ciliophagy also in asthma and may have implications upon 
mucociliary clearance (MCC). A question that arises is whether airway wall changes in 
asthmatics are contributing to increased expression of Beclin1 in cilia, or whether the increased 
expression of Beclin1 in the cilia is influencing the cellular stimulation of airway remodeling. 
The effect that this upregulation of Beclin-1 in asthmatic ciliated cells has upon autophagy flux 
in other respiratory cells of the airway wall requires further investigation. One limitation of this 
study is the coincidence of all patients included being male, and this coincidence is unavoidable 
with the limited access to asthmatic and non-asthmatic tissue we have at this time. A further 
limitation is our lack of addressing the different phenotypes presented in asthma diagnosis such 
as eosinophilic, neutrophilic, or paucigranulocytic asthma. We believe the patient group in this 
study is reflective of mild-moderate asthma i.e. it represents a greater asthma population in the 
general public. In future we would like to investigate whether expression of autophagy is 
associated with asthma severity. 
We further investigated whether an inhibitor of autophagy: CQ has any therapeutic 
value in both acute (sub-chronic) and chronic (treatment) model of allergen (HDM)-induced 
asthma in mice. A few clinical studies in the early 80’s and 90’s have demonstrated that 
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hydroxychloroquine can be used as an effective treatment for severe asthma as it has a steroid-
sparing effect (38). Since then there has been a lack of big prospective clinical trials to further 
validate these original observations. Our preclinical data clearly demonstrates that CQ is 
effective in blocking the influx of immune cells both in BAL and lung tissue. Further our data 
uncover novel therapeutic effects of CQ in asthma as it reduces features of airway remodeling 
by preventing accumulation of mucus and ECM matrix protein collagen-1 in the lung. The 
inhibition of autophagy by CQ was supported with our immunohistochemical analysis in the 
chronic mouse model showing decreased expression in of Beclin-1 and ATG5, and increased 
expression of p62 in the ASM bundles of CQ+HDM-treated mice in comparison with HDM-
challenged mice. We also found reduction in ASM mass as shown by reduced staining for sm-
a-actin in the airways of mice treated with CQ. The mechanisms of the beneficial effect of CQ 
relies on blocking the release of pro-fibrotic cytokine TGFβ1 in the BAL of HDM-challenged 
mice after treating with CQ. It is well known that TGFβ1 drives fibrotic changes in the lung 
and its levels are elevated in asthma (39) and it is emerging that the autophagy pathway may 
interact with the ECM and affect cytokine secretion (7, 40). We have shown in vitro that upon 
stimulation with TGFβ1, human ASM cells produced greater amounts of collagen 1A, have 
increased expression of Beclin-1 and LC3B-II, and greater phosphorylation of SMAD2/3 in a 
time-dependent manner, which supports the growing notion that TGFβ1 concomitantly induces 
autophagy and drives pro-fibrotic signaling. CQ acts by inhibiting autophagy and reducing 
TGFβ1-dependent pro-fibrotic signaling in asthma. This was confirmed with the co-treatment 
of CQ and TGFβ1 resulting in a time-dependent reduction in collagen A1, diminished 
expression of Beclin-1 and LC3B-II, and reduced phosphorylation of SMAD2/3. These 
beneficial effects of modulating autophagy using CQ in disease setting (mouse models) also 
translated in reducing development of AHR (data not shown for chronic model) to MCh which 
is another hallmark feature of allergic asthma. 
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Further our mouse models demonstrated clear initiation (in the 3-week model) and 
establishment (in 5-week model) of airway remodeling as seen by increase in mucus release, 
accumulation of collagen-1 in the lung and activation of autophagy pathway, reflected by an 
increase in autophagy markers in the lung. CQ treatment in HDM-challenged mice clearly 
blocked features of airway remodeling in the lung with a concomitant reduction in autophagy 
as seen with reduction in Beclin-1 and ATG-5 proteins. This clearly states that CQ works at 
multiple levels to provide therapeutic benefit in asthma: it blocked inflammation, reduced 
mucus secretion, inhibited TGFβ1 release in BAL, and reduced release and accumulation of 
ECM proteins in the lung, leading to reduction in AHR. This is achieved by modulation of 
autophagy pathway as CQ inhibits overall autophagy flux by increasing the pH in the lysosome, 
preventing the fusion of the autophagolysosome and the subsequent degradation of lysosomal 
components (41). Though autophagy modulation with CQ however is not highly selective as it 
has a number of other pharmacological effects, at the concentrations used in this study, Beclin-
1 and ATG-5 were reduced by CQ. Therefore, we are highly confident of these findings that 
CQ works in an experimental asthma model by modulation of autophagy pathway. Originally 
an anti-malarial and anti-arthritis drug (42), CQ has been shown to also target inwardly 
rectifying potassium (Kir) channels (43), and by disrupting the blood-retinal barrier it has the 
potential to cause retinopathy through the binding to melanin and toxic sequestration in the eye 
(44). Compounds with greater specificity are now being considered in the target of the 
autophagy pathway. Bafilomycins are macrolide antibiotics derived from Streptomyces griseus 
bacteria that inhibit Vacuolar-type H+-ATPase (V-ATPase). At high concentration, 
bafilomycin is capable of blocking late-phase autophagy through significant cytosolic 
acidification (45). 3-methyladenine (3-MA) also has the ability to suppress the formation of 
autophagosomes specifically targeting autophagy through the inhibition of class III PI3K (46). 
However, 3-MA is found to have a dual role in autophagy modulation. It surprisingly promotes 
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autophagy flux with prolonged treatment under nutrient-rich conditions as well as having the 
capability of suppressing starvation-induced autophagy (47). LY294002, derived from the 
flavonoid Quercetin (48), inhibits PI3K activity (49) and belongs with the emerging safe 
therapeutics with the potential to treat airway remodeling. LY294002 treatment in mice 
challenged with Follistatin-related protein 1 (FSTL1) (linked with the promotion of both EMT 
and autophagy) has shown early signs of implication in the attenuation of airway remodeling 
(50).  
Inhibition of autophagy, as shown here with CQ treatment, is entwined with an 
upstream TGFβ1 response and the level of collagen production. As it has previously been 
shown in hepatic cells and cardiomyocytes, TGFβ concomitantly influences features of 
remodeling as well as regulating levels of autophagy (7, 30), we introduce and provide 
evidence that a similarly concomitant pathway is occurring both in vitro and in vivo. This 
pathway, we believe, has the greatest influence in the ASM of the large airways as seen in 
asthmatic lungs which is also replicated in vitro using primary human ASM cells where we 
found TGFβ1 concomitantly induced both pro-fibrotic signaling and autophagy. We have 
shown an increase (and supporting decrease for p62) in several vital autophagy-linked proteins 
in the large airway ASM bundles. We have shown that inhibition of autophagy in murine 
models can; attenuate inflammation, clear mucus production, reduce levels of TGFβ1 in the 
BAL, and ultimately reduce airway remodeling and prevent bronchoconstriction. Thus, our 
study indicates that in asthmatic airways autophagy is enhanced, which we believe contributes 
to remodeling in a TGFβ1-dependent manner, and inhibition of autophagy is an attractive target 
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Table 1. Demographic data for the asthmatic patients and non-asthmatic control 
subjects (Data expressed as numbers of subjects or medians (range)) 
  
Large airway Demographics 
Groups (numbers) Non-Asthmatic (10) Asthmatic (6) 
Age, median (range)          55 (19-67)       48 (15-80) 
Male/Female              10/0           6/0 
Small airway Demographics 
Groups (numbers) Non-Asthmatic (10) Asthmatic (7) 
Age, median (range)                             52 (25-69)                 53.5 (15-80) 





Figure 1. Histological evidence of airway remodeling in the large airways of the selected 
asthmatic patients. Non-asthmatic (A) and asthmatic (B) airways were stained with masson’s 
trichrome staining as described in the methods. Original magnification, ×50 (A, B).  Arrows 
indicate the RBM and arrowheads indicate the epithelium (C, D). ASM bundles are indicated 
by white arrowheads (E, F). Smooth muscle bundles are stained (red) and connective tissue 
(blue). Original magnification, ×400 (C, D, E, F). The epithelium (G), RBM thickness (H), 
Lamina propria depth (I), the proportion of ASM in the asthmatic airway wall (J), 
inflammation score in sub-mucosa (K); eosinophil (L), neutrophil (M) and macrophage (N) 
counts per mm2 were quantified. (Data is expressed as mean ± SD or SEM; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001).  
 
Figure 2. Expression of autophagy markers in the large airway epithelium of asthmatic and 
non-asthmatic tissue. Asthmatic and non-asthmatic tissue were immunohistochemically 
stained for Beclin1 (A, B), ATG5 (D, E), LC3B (G, H), and p62 (J, K). Original magnification, 
×400. Positive area for each of these markers in the epithelium was quantified (C, F, I, L).  
 
Figure 3. Expression of autophagy markers in the large airway ASM bundles of asthmatic and 
non-asthmatic tissue. Asthmatic and non-asthmatic tissue were immunohistochemically 
stained for Beclin1 (A, B), ATG5 (D, E), LC3B (G, H), and p62 (J, K). Original magnification, 
×400. Arrowheads indicate ASM bundles. Positive area for each of these markers in the ASM 




Figure 4. Expression of autophagy markers in the small airway epithelium of asthmatic and 
non-asthmatic tissue. Asthmatic and non-asthmatic tissue were immunohistochemically 
stained for Beclin1 (A, B), ATG5 (D, E), LC3B (G, H), and p62 (J, K). Original magnification, 
×400. Arrowheads indicate epithelium. Positive area for each of these markers in the epithelium 
was quantified (C, F, I, L). Data is expressed as mean ± SD; *p<0.05. 
 
Figure 5. Expression of autophagy markers in the small airway ASM bundles of asthmatic and 
non-asthmatic tissue. Asthmatic and non-asthmatic tissue were immunohistochemically 
stained for Beclin1 (A, B), ATG5 (D, E), LC3B (G, H), and p62 (J, K). Original magnification, 
×400. Positive area for each of these markers in the epithelium was quantified (C, F, I, L).  
 
Figure 6. Expression of Beclin1 in cilia lining large airway epithelium of asthmatics. Non-
asthmatic large airway epithelium (A) and asthmatic large airway epithelium (B) 
immunohistochemically stained for Beclin-1. Arrowheads indicate cilia. Original 
magnification, ×1000.  Representation of the number of patients (Asthma v Non-asthma) with 
Beclin-1 positivity in cilia (C).  
 
Figure 7. Concomitant induction of pro-fibrotic signaling and autophagy by TGF1 in vitro. 
Human airway smooth muscle cells were treated with either TGF1 (2.5ng/ml) or TGF1 
(2.5ng/ml) + CQ (50µM) for 0, 24, 48, 72 and 96 hours. Cell lysates were prepared, and 
immunoblotting was performed for collagen-1A, phospho-SMAD2/3, total SMAD2/3, Beclin-
1, LC3BI/II while GAPDH was used as a loading control. Data shown is representative of 4-




Figure 8. Mouse model of allergic asthma (A). Female mice at 8-weeks were challenged intra 
nasally (i.n.) with HDM 5 days/week for 3 weeks. Autophagy inhibitor chloroquine (CQ, 
50mg/kg) was administered 30 mins prior to each HDM challenge, 24h after the last challenge, 
BAL and lung tissue was collected for further analysis. Inflammation in the BAL fluid was 
measured in saline controls (B), HDM-challenged mice (C), and the HDM+CQ group (D). 
H&E staining was used to measure tissue inflammation in the saline controls (E), HDM-
challenged mice (F), and the HDM+CQ group (G). Periodic Acid-Schiff (PAS) measured 
mucus production in the saline controls (H), HDM-challenged mice (I), and the HDM+CQ 
group (J). CQ treatment in the HDM-challenged group reduced influx of total immune cells 
(K), eosinophils (L), neutrophils (M), macrophages remain unchanged (N). Further, inhibition 
of autophagy reduced profibrotic cytokine TGFβ1 (O) levels in BAL and also reduced the 
amount of soluble lung collagen in tissue lysates (P). One-way ANOVA: saline vs HDM 
*p<0.001; HDM vs HDM+CQ #p<0.05 with Bonferroni multiple comparisons test. Flexivent 
analysis revealed reduction in MCh-induced AHR in CQ-treated group when compared to 
HDM-challenged group alone (Q). Two-way ANOVA: saline vs HDM *p<0.05; **p<0.01; 
****p<0.0001 (at 25, 50 and 100 mg/ml); HDM vs HDM+CQ #p<0.05; ##p<0.01 (at 25, 50 
and 100 mg/ml). Representative protein immunoblots for Collagen1A, Beclin1 and ATG-5 in 
lung tissue lysates from Saline, HDM- and HDM+CQ-treated mice (R). Mouse data shown 
represent Mean ± SEM from n=6-7 per group. 
 
Figure 9. Mouse model of chronic allergic asthma (A). Female mice at 8-weeks were 
challenged intra nasally (i.n.) with HDM 5 days/week for 5 weeks. At week 4 for the remaining 
2 weeks, autophagy inhibitor chloroquine (CQ, 50mg/kg) was administered 30 mins prior to 
each HDM challenge, 24h after the last challenge, BAL and lung tissue was collected for 
further analysis. (B) H&E staining was used to measure tissue inflammation in the saline 
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controls, HDM-challenged mice, and the HDM+CQ group. Masson’s trichrome staining was 
used to measure connective tissue deposition and smooth muscle mass in the saline controls, 
HDM-challenged mice, and the HDM+CQ group. Periodic Acid-Schiff (PAS) measured mucus 
production in the saline controls, HDM-challenged mice, and the HDM+CQ group. α-Smooth 
muscle actin staining was used to stain smooth muscle cells in the saline controls, HDM-
challenged mice, and the HDM+CQ group. (C) Imunohistochemical staining was used to 
measure the expression of autophagy proteins in the ASM bundles of the mice. Beclin-1 
expression was measured in the saline controls, HDM-challenged mice, and the HDM+CQ 
group. ATG5 expression was measured in the saline controls, HDM-challenged mice, and the 
HDM+CQ group. LC3B expression was measured in the saline controls, HDM-challenged 
mice, and the HDM+CQ group. p62 expression was measured in the saline controls, HDM-
challenged mice, and the HDM+CQ group. Positive area for each of these markers in the ASM 
was quantified (D, E, F & G). (Data is expressed as mean ± SD or SEM, n=4-6). 
 
